Variances in patterns of care for patients with prostate cancer failing primary therapy

	Tweet

Variables that impact management of failed primary therapy for prostate cancer (CaP) are not well defined.

In the epub version of Cancer, Dr. Krupski and associates report on the patterns of secondary treatments in a large registry-based research study.

They sought to determine whether geographic region, ethnicity or socioeconomic status influences the receipt of secondary treatment.

The investigators used the Surveillance, Epidemiology and End Result (SEER) and Medicare databases for the years 1991 to 2001, identifying patients who were diagnosed before 1995. The SEER database tracks patients only for 4 months and lacks individual socioeconomic data. Linkage with Medicare claims permitted ascertainment of this data.

Patients undergoing primary treatment with radical prostatectomy (RP), radiotherapy (XRT), brachytherapy (BT), or combinations with androgen deprivation were identified. Androgen deprivation (AD) therapy alone was excluded. AD initiated 12 months or longer after RP was considered secondary therapy.

A cohort of 65,266 patients was studied, and 81-89% received no additional treatment. Some form of secondary treatment was given to 10,200 men. As patient age increased, the number receiving secondary treatment decreased. One-third of all patients requiring secondary therapy had Grade 3 tumors. Geographically, Los Angeles had surgical rates almost twice other regions and Detroit had XRT rates twice other regions. Secondary therapies varied almost 3-fold among SEER regions with the lowest rates in New Mexico and the highest in Detroit. The later the year of diagnosis the more likely the patients were to receive secondary therapy. Patients in Connecticut, Iowa and Los Angeles were more likely to receive secondary therapy and those in San Francisco and Seattle were less likely.

These data support that there a wide variation in regional administration of secondary treatment for CaP failure following primary therapy.

Written by Christopher P. Evans, MD - UroToday

RELATED STORIES:
USC Leads International Program Aimed At Identifying Prostate Cancer Risk   Men Who Take Aspirin Have Significantly Lower PSA Levels   New, non-invasive prostate cancer test beats PSA in detecting prostate cancer, researchers report   New diagnostic tool for prostate cancer   Study Drug Holds Promise As Alternative to Castration For Early Prostate Cancers   Freezing prostate cancer does a man’s body good   Complementary Alternative Medical (CAM) Therapy and Prostate Cancer   Pomegranate Juice Slows PSA Acceleration Rate After Prostate Cancer Surgery, Radiation   Program boosts life for prostate cancer patients   Mediterranean Diet May Help Prevent Prostate Cancer   Gonorrhea linked to higher prostate cancer risk   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Minimally invasive breakthrough for men’s enlarged prostates improves symptoms   Dehydrated tomatoes show promise for preventing prostate cancer   Mushroom extract may boost prostate cancer drug   New X-ray approach targets prostate cancer   New research could affect future treatment options for prostate cancer   New research model of human prostate cancer shows cancer development   Smoking Associated with Worse Outcomes in Patients with Prostate Cancer Treated by Radical Radiother   No Evidence That Widely Prescribed Statins Protect Against Prostate Cancer   Guide aims to help men understand prostate cancer   Possible link found between x-rays and prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]